High-dose interferon-α therapy lowers the levels of serum fibrogenesis markers over 5 years in chronic hepatitis C

Hepatology Research

Volumn 25, Issue 1, 2003, Pages 22-31

  Abe, Shintaro ^a   Tabaru, Akinari ^a   Ono, Masami ^a   Tai, Mayumi ^a   Narita, Ryouichi ^a   Moriyama, Atsushi ^a   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Chronic hepatitis C; Hepatic fibrogenesis; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; COLLAGEN TYPE 4; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL OBSERVATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FIBROGENESIS; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW;

EID: 0037237872     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00203-6     Document Type: Article

References (35)

1. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
2. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
3. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989:321:1501-6.
4. Di Bisceglie AM, Martin P, Kassiandes C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
5. Babbs C, Smith A, Hunt LP, Rowan BP, Haboubi NY, Warnes TW. Type III procollagen propeptide: a marker of disease activity and prognosis in primary biliary cirrhosis. Lancet 1988;1:1021-4.
6. Guéchot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III amino-terminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994;20:388-93.
7. Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. Hepatology 1994;20:780-7.
8. Ueno T, Inuzuka S, Torimura T, et al. Significance of serum type IV collagen levels in various liver diseases. Measurement with one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen. Scand J Gastroenterol 1992;27:513-20.
9. Yabu K, Kiyosawa K, Mori H, et al. Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 1994;29:474-9.
10. Yamada M, Fukuda Y, Koyama Y, et al. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996;11:646-51.
11. Ninomiya T, Yoon S, Hayashi Y, et al. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-α: histological evaluation by a modified histological activity index scoring system. J Gastroenterol Hepatol 1998;13:68-74.
12. Ishibashi K, Kashiwagi T, Ito A, et al. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Hepatology 1996;24:27-31.
13. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1995;22:426-31.
14. Capra F, Casaril M, Gabrielli GB, et al. α-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markets. J Hepatol 1993;18:112-8.
15. Castilla A, Camps-Bansell J, Civeira M-P, Prieto J. Lymphoblastoid α-interferon for chronic hepatitis C: a randomized controlled study. Am J Gastroenterol 1993;88:233-9.
16. Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-α therapy: including quantitative assessment by a morphometric method. J Gastroenterol 2000;35:105-11.
17. Castilla A, Prieto J, Faustro N. Transforming growth factor β1 and α in chronic liver disease: effects of interferon α therapy. N Engl J Med 1991;324:933-40.
18. Duchatelle V, Marcellin P, Giostra E, et al. Changes in liver fibrosis at the end of α interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol 1998;29:20-8.
19. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon α treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The multivire group. Gastroenterology 1999;116:378-86.
20. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
21. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis-a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
22. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic viral hepatitis. N Engl J Med 1993;328:1797-801.
23. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis a prospective observation of 2215 patients. J Hepatol 1998;28:930-8.
24. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-81.
25. Guerret S, Desmouliere A, Chossegros P, et al. Long-term administration of interferon-α in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J Viral Hepat 1999;6:125-33.
26. Risteli J, Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 1995;22(Suppl. 2):77-81.
27. Biagini G, Ballardini G. Liver fibrosis and extracellular matrix. J Hepatol 1989;8:115-24.
28. Niemela O, Risteli L, Sotaniemi EA, Risteli J. Type IV collagen and laminin-related antigens in human serum in alcoholic liver disease. Eur J Clin Invest 1985;15:132-7.
29. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984;10:795-800.
30. Dhanani S, Huang M, Wang J, Dubinett SM. Interferon-α inhibits murine macrophage transforming growth factor-β mRNA expression. Inflammation 1994;18:301-9.
31. Tredget EE, Wang R, Shen Q, Scott PG, Ghahary A. Transforming growth factor-β mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-α and IFN-γ in vitro and in vivo. J Interferon Cytokine Res 2000;20:143-51.
32. Tredget EE, Shankowsky HA, Pannu R, et al. Transforming growth factor-β in thermally injured patients with hypertrophic scars: effects of interferon α-2b. Plast Reconstr Surg 1998;102:1317-28 (discussion: 1329-1330).
33. Gallorini A, Plebani M, Pontisso P, et al. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with α-2A interferon. Liver 1994;14:257-64.
34. Teran JC, Mullen KD, Hoofnagle JH, McCullough AJ. Decrease in serum levels of connective tissue turnover during and after treatment of chronic hepatitis B treated with interferon-α. Hepatology 1994;19:849-56.
35. Weigand K, Zaugg PY, Frei A, Zimmermann A. Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology 1984;4:835-8.